Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J. Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness

doi:10.1111/trf.15344

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Chintamani Atreya, Simone Glynn, Michael Busch, Steve Kleinman, Edward Snyder, Sara Rutter, James AuBuchon, Willy Flegel, David Reeve, Dana Devine, Claudia Cohn, Brian Custer, Raymond Goodrich, Richard J. Benjamin, Anna Razatos, Jose Cancelas, Stephen Wagner, Michelle Maclean, Monique Gelderman, Andrew CapPaul Ness

School of Medicine

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	3002-3025
Number of pages	24
Journal	Transfusion
Volume	59
Issue number	9
DOIs	https://doi.org/10.1111/trf.15344
State	Published - Sep 1 2019

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Hematology

Access to Document

10.1111/trf.15344

Cite this

Atreya, C., Glynn, S., Busch, M., Kleinman, S., Snyder, E., Rutter, S., AuBuchon, J., Flegel, W., Reeve, D., Devine, D., Cohn, C., Custer, B., Goodrich, R., Benjamin, R. J., Razatos, A., Cancelas, J., Wagner, S., Maclean, M., Gelderman, M., ... Ness, P. (2019). Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026). Transfusion, 59(9), 3002-3025. https://doi.org/10.1111/trf.15344

Atreya, C, Glynn, S, Busch, M, Kleinman, S, Snyder, E, Rutter, S, AuBuchon, J, Flegel, W, Reeve, D, Devine, D, Cohn, C, Custer, B, Goodrich, R, Benjamin, RJ, Razatos, A, Cancelas, J, Wagner, S, Maclean, M, Gelderman, M, Cap, A & Ness, P 2019, 'Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)', Transfusion, vol. 59, no. 9, pp. 3002-3025. https://doi.org/10.1111/trf.15344

@article{64b5ee1d02624bd79d77b67e5bbdc33a,

title = "Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)",

author = "Chintamani Atreya and Simone Glynn and Michael Busch and Steve Kleinman and Edward Snyder and Sara Rutter and James AuBuchon and Willy Flegel and David Reeve and Dana Devine and Claudia Cohn and Brian Custer and Raymond Goodrich and Benjamin, {Richard J.} and Anna Razatos and Jose Cancelas and Stephen Wagner and Michelle Maclean and Monique Gelderman and Andrew Cap and Paul Ness",

note = "Funding Information: The work was supported by a grant (project ID Z99 CL999999) from the Intramural Research Program of the NIH Clinical Center. Funding Information: The organizing committee thanks CBER Director Dr. Marks and OBRR Director Dr. Verdun for their constant support and providing direction to the committee. Dr. Flegel thanks Harvey Gordon Klein, MD, for review of the manuscript and comments and acknowledges the late Sherry Lynne Sheldon, MT(ASCP)SBB, whose contribution as laboratory supervisor in the Laboratory Services Section was critical for efficiently implementing the technology in a timely manner under fiscal constraints. PRT PLTs remain S.L. Sheldon's legacy to the patients and their safety at the NIH Clinical Center. Dr. Benjamin acknowledges that INTERCEPT RBCs are being developed under contract with the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services. SK is a consultant to Cerus, manufacturer of the Intercept system and serves on Medical Advisory Board of Creative Testing Solutions (CTS). ES is PI for the Cerus PIPER Phase IV clinical study at the Yale site?he receives no personal remuneration. SR has nothing to disclose. WF states that the views expressed do not necessarily represent the view of the National Institutes of Health, the Department of Health and Human Services, or the US Federal Government and no financial relationship relevant for this publication. RB is an employee and stockholder in Cerus Corporation, a manufacturer of pathogen reduction technologies. AR is an employee of Terumo BCT.",

year = "2019",

month = sep,

day = "1",

doi = "10.1111/trf.15344",

language = "English (US)",

volume = "59",

pages = "3002--3025",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

AU - Atreya, Chintamani

AU - Glynn, Simone

AU - Busch, Michael

AU - Kleinman, Steve

AU - Snyder, Edward

AU - Rutter, Sara

AU - AuBuchon, James

AU - Flegel, Willy

AU - Reeve, David

AU - Devine, Dana

AU - Cohn, Claudia

AU - Custer, Brian

AU - Goodrich, Raymond

AU - Benjamin, Richard J.

AU - Razatos, Anna

AU - Cancelas, Jose

AU - Wagner, Stephen

AU - Maclean, Michelle

AU - Gelderman, Monique

AU - Cap, Andrew

AU - Ness, Paul

N1 - Funding Information: The work was supported by a grant (project ID Z99 CL999999) from the Intramural Research Program of the NIH Clinical Center. Funding Information: The organizing committee thanks CBER Director Dr. Marks and OBRR Director Dr. Verdun for their constant support and providing direction to the committee. Dr. Flegel thanks Harvey Gordon Klein, MD, for review of the manuscript and comments and acknowledges the late Sherry Lynne Sheldon, MT(ASCP)SBB, whose contribution as laboratory supervisor in the Laboratory Services Section was critical for efficiently implementing the technology in a timely manner under fiscal constraints. PRT PLTs remain S.L. Sheldon's legacy to the patients and their safety at the NIH Clinical Center. Dr. Benjamin acknowledges that INTERCEPT RBCs are being developed under contract with the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services. SK is a consultant to Cerus, manufacturer of the Intercept system and serves on Medical Advisory Board of Creative Testing Solutions (CTS). ES is PI for the Cerus PIPER Phase IV clinical study at the Yale site?he receives no personal remuneration. SR has nothing to disclose. WF states that the views expressed do not necessarily represent the view of the National Institutes of Health, the Department of Health and Human Services, or the US Federal Government and no financial relationship relevant for this publication. RB is an employee and stockholder in Cerus Corporation, a manufacturer of pathogen reduction technologies. AR is an employee of Terumo BCT.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85066835721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066835721&partnerID=8YFLogxK

U2 - 10.1111/trf.15344

DO - 10.1111/trf.15344

M3 - Article

C2 - 31144334

AN - SCOPUS:85066835721

SN - 0041-1132

VL - 59

SP - 3002

EP - 3025

JO - Transfusion

JF - Transfusion

IS - 9

ER -

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this